NASDAQ:FGENFibroGen Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding FibroGen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $32.57 -1.47 (-4.32 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$31.65Now: $32.57▼$34.4250-Day Range$23.30MA: $37.16▼$45.7052-Week Range$22.65Now: $32.57▼$55.63Volume349,586 shsAverage Volume919,776 shsMarket Capitalization$2.87 billionP/E RatioN/ADividend YieldN/ABeta1.71 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingFibroGen has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.00, FibroGen has a potential upside of 59.7% from its current price of $32.57.Amount of Analyst CoverageFibroGen has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesFibroGen has received 314 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFibroGen has received 302 “underperform” votes. (Add your “underperform” vote.)Community SentimentFibroGen has received 50.97% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote “Outperform” if you believe FGEN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFibroGen does not currently pay a dividend.Dividend GrowthFibroGen does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, FibroGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,863,409.00 in company stock.Percentage Held by InsidersOnly 8.96% of the stock of FibroGen is held by insiders.Percentage Held by Institutions69.66% of the stock of FibroGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for FibroGen are expected to decrease by -16.96% in the coming year, from ($1.12) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of FibroGen is -33.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of FibroGen is -33.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFibroGen has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FGEN Previous Symbol CUSIPN/A CIK921299 Webhttp://www.fibrogen.com/ Phone415-978-1200Debt Debt-to-Equity Ratio0.07 Current Ratio6.84 Quick Ratio6.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$256.58 million Price / Sales11.17 Cash FlowN/A Price / Cash FlowN/A Book Value$6.14 per share Price / Book5.30Profitability EPS (Most Recent Fiscal Year)($0.89) Net Income$-76,970,000.00 Net Margins-30.00% Return on Equity-13.35% Return on Assets-8.85%Miscellaneous Employees461 Outstanding Shares88,000,000Market Cap$2.87 billion Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive FGEN News and Ratings via Email Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:FGEN Rates by TradingView FibroGen (NASDAQ:FGEN) Frequently Asked Questions How has FibroGen's stock been impacted by COVID-19 (Coronavirus)? FibroGen's stock was trading at $35.40 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FGEN stock has decreased by 8.0% and is now trading at $32.57. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of FibroGen? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for FibroGen. When is FibroGen's next earnings date? FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for FibroGen. How were FibroGen's earnings last quarter? FibroGen Inc (NASDAQ:FGEN) issued its earnings results on Monday, March, 2nd. The biopharmaceutical company reported ($1.12) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.53. The biopharmaceutical company earned $7.97 million during the quarter, compared to analysts' expectations of $40.32 million. FibroGen had a negative return on equity of 13.35% and a negative net margin of 30.00%. The business's quarterly revenue was down 92.6% compared to the same quarter last year. During the same period in the previous year, the business posted $0.23 EPS. View FibroGen's earnings history. What price target have analysts set for FGEN? 5 equities research analysts have issued 12-month price targets for FibroGen's stock. Their forecasts range from $40.00 to $72.00. On average, they expect FibroGen's stock price to reach $52.00 in the next year. This suggests a possible upside of 59.7% from the stock's current price. View analysts' price targets for FibroGen. Has FibroGen been receiving favorable news coverage? News stories about FGEN stock have been trending very negative on Saturday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. FibroGen earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutFibroGen. Are investors shorting FibroGen? FibroGen saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 5,390,000 shares, a decline of 7.7% from the February 13th total of 5,840,000 shares. Based on an average daily volume of 612,100 shares, the short-interest ratio is currently 8.8 days. Approximately 6.7% of the shares of the stock are short sold. View FibroGen's Current Options Chain. Who are some of FibroGen's key competitors? Some companies that are related to FibroGen include Alnylam Pharmaceuticals (ALNY), Genmab A/S (GNMSF), Ono Pharmaceutical (OPHLF), Beigene (BGNE), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Sarepta Therapeutics (SRPT), Catalent (CTLT), Mylan (MYL), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Horizon Therapeutics (HZNP), Perrigo (PRGO) and Jazz Pharmaceuticals (JAZZ). What other stocks do shareholders of FibroGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), ALJ Regional (ALJJ) and Allergan (AGN). Who are FibroGen's key executives? FibroGen's management team includes the following people: Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 65)Mr. Pat Cotroneo, Sr. VP of Fin. & CFO (Age 55)Dr. K. Peony Yu, Chief Medical Officer (Age 57)Mr. Julian N. Stern, Sec. (Age 94)Dr. Barry A. Berkowitz, Founder When did FibroGen IPO? (FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers. What is FibroGen's stock symbol? FibroGen trades on the NASDAQ under the ticker symbol "FGEN." Who are FibroGen's major shareholders? FibroGen's stock is owned by a number of institutional and retail investors. Top institutional investors include Woodstock Corp (0.03%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View institutional ownership trends for FibroGen. Which major investors are buying FibroGen stock? FGEN stock was acquired by a variety of institutional investors in the last quarter, including Woodstock Corp. View insider buying and selling activity for FibroGen. How do I buy shares of FibroGen? Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is FibroGen's stock price today? One share of FGEN stock can currently be purchased for approximately $32.57. How big of a company is FibroGen? FibroGen has a market capitalization of $2.87 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe. View additional information about FibroGen. What is FibroGen's official website? The official website for FibroGen is http://www.fibrogen.com/. How can I contact FibroGen? FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected] This page was last updated on 4/4/2020 by MarketBeat.com StaffFeatured Article: What is quantitative easing?
